FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Pinealon

EDR peptide / Glu-Asp-Arg

Longevity & Anti-Aging

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.

작용 메커니즘

Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual administration may improve bioavailability. Cycles repeated every 3-6 months.

연구 노트

Clinical Research Status

Pinealon has been studied primarily in Russian clinical research settings, with publications appearing in Russian biomedical journals and the St. Petersburg Institute of Bioregulation and Gerontology. Clinical studies in elderly patients have reported improvements in sleep quality, cognitive function, and normalization of melatonin cycling following oral or intranasal administration. It is registered and available as a dietary supplement in Russia but has not undergone Western regulatory review or FDA evaluation.

Key Published Findings

Research by Khavinson's group demonstrates that Pinealon can penetrate cell membranes and nuclear envelopes to interact with specific DNA sequences, potentially regulating gene expression related to pineal gland function. In vitro studies show the peptide promotes neuronal survival under oxidative stress conditions and normalizes circadian gene expression patterns. Animal studies indicate restoration of melatonin synthesis capacity in aged rats and improvement of learning and memory in models of accelerated aging.

Safety Profile

As a naturally occurring amino acid sequence found in human tissue, Pinealon is reported to have an excellent safety profile with no documented adverse effects in available clinical literature. The tripeptide structure is rapidly metabolized into constituent amino acids (glutamic acid, aspartic acid, arginine), minimizing accumulation risk. No drug interactions have been formally documented, though caution is theoretically warranted when combining with exogenous melatonin or other sleep-modulating compounds.

Comparison to Related Compounds

Pinealon differs from exogenous melatonin supplementation by theoretically restoring endogenous melatonin production capacity rather than simply replacing the hormone. Compared to the related Khavinson peptide Epithalon (which targets telomerase in the pineal gland), Pinealon focuses on functional normalization rather than cellular longevity mechanisms. Within the bioregulator peptide family, each compound is tissue-specific: Pinealon targets the pineal gland, Cortexin targets the brain cortex, and Retinalamin targets the retina.

Community Observations

Users typically report improved sleep onset latency and sleep quality within 1-2 weeks of sublingual or intranasal administration. Some users prefer Pinealon over exogenous melatonin due to the absence of morning grogginess and more natural-feeling sleep architecture. Sourcing is primarily limited to Russian pharmacies or specialized peptide suppliers, with quality verification being a common concern in the community.

반감기

~15-30 minutes

재조성

N/A (typically oral/sublingual capsule)

보관

건조한 상태

Room temperature. Protect from moisture.

재조성된 상태

N/A (oral form)

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

EDR peptideGlu-Asp-Arg

자주 묻는 질문

Pinealon란 무엇인가요?

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.

Pinealon는 어떻게 작용하나요?

Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.

Pinealon의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Pinealon의 반감기는 얼마인가요?

~15-30 minutes

Pinealon의 다른 이름은 무엇인가요?

EDR peptide, Glu-Asp-Arg

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기